

REMARKS

This application is a continuation under 37 C.F.R. 1.53(b) of prior application Serial No. 10/044,221 and is filed in lieu of a response to the outstanding Office Action mailed June 6, 2003 in said prior application. Pursuant to the Petition under 37 C.F.R. 1.136(a) for a three-month extension of time to December 6, 2003, filed in application Serial No. 10/044,221 (copy herewith), the instant continuation is timely filed.

The specification is amended to insert a cross-reference to prior copending application Serial No. 10/044,221 and application Serial No. 09/331,524.

Claims 1-7, which are directed to the subject matter which was elected for prosecution and allowed in U.S. application Serial No. 09/331,524, have been canceled.

Claims 8-13 are amended to put them in appropriate U.S. claim format.

In view of the cancellation of claim 1, claim 13, which is directed to the combination of a compound of formula (I) as defined in claim 1 with a compound useful in the symptomatic treatment of DAT, is amended to specifically recite the compounds of formula (I).

Claim 12 as amended and new claims 14 and 15 correspond to original multiply dependent claim 12 written in singly dependent form.

New claim 16 is directed to the use of the composition of claim 13. Support for this claim is found, for example, in the specification at page 9, line 37 to page 10, line 8.


Claim 17 is drawn to the compounds of claim 8 in which R'₂ contains a phenyl group, and similarly claim 18 is directed to those species of claim 10 in which R'₂ contains a phenyl group.

No new matter is added by the foregoing amendments.

Claims 8-18 are in the application as amended.

Respectfully submitted,

Date: 12/5/03


Paul E. Dupont
Reg. No. 27,438

Address:
Patent Department
Sanofi-Synthelabo Inc.
9 Great Valley Parkway
Malvern, PA 19355
Telephone No. (610) 889-6338
Facsimile: (610) 889-8799